CYCN: DEF 14A · proxy statement
Korsana Biosciences (formerly Cyclerion Therapeutics, ticker changed from CYCN to KRSA after its September 8, 2026 merger with Legacy Korsana) has called a special meeting for November 13, 2026 to again seek shareholder approval of a redomestication from Massachusetts to the Cayman Islands. The proposal already failed at the August 26, 2026 annual meeting, winning about 61.8% of votes cast but only about 44.8% of shares outstanding, short of the two-thirds standard. Proposal No. 1 requires approval by at least 30,360,906 of the 45,541,358 shares outstanding, meaning every unvoted share counts as a vote against. The board says the move would reduce litigation risk against directors and officers and provide transaction flexibility; critics would note it also introduces a classified board, Cayman exclusive forum, and preferred-share consent rights that could deter takeovers.
CYCN: PRE 14A · proxy statement
Korsana Biosciences (formerly Cyclerion Therapeutics) filed a preliminary proxy for a special meeting on November 13, 2026 to again seek shareholder approval to redomesticate from Massachusetts to the Cayman Islands. The identical proposal failed at the August 26, 2026 annual meeting, winning roughly 61.8% of votes cast but only about 44.8% of the 4,681,351 shares outstanding, short of the two-thirds-of-outstanding-shares standard Massachusetts law requires. The board argues Cayman law reduces litigation risk and increases transaction flexibility, but the new Cayman Articles would introduce a classified board, exclusive Cayman forum, and other anti-takeover provisions, and the Series B preferred holders would retain significant change-of-control consent rights.
CYCN: SCHEDULE 13D · ownership disclosure
Venrock Healthcare Capital Partners' investment vehicles, along with partners Bong Koh and Nimish Shah, filed a Schedule 13D disclosing beneficial ownership of 4,552,277 shares of Korsana Biosciences common stock, equal to a reported 9.9% stake (9.995% before EDGAR rounding). The stake stems from roughly $134.8 million the group invested in Old Korsana Biosciences between November 2024 and the September 8, 2026 completion of the merger between Cyclerion Therapeutics and private Old Korsana, after which the combined company was renamed Korsana Biosciences; Old Korsana shares converted at a 0.2074 exchange ratio. Holdings comprise common shares, Series B non-voting preferred stock convertible into 1,000 common shares each, and pre-funded warrants with a $0.0001 exercise price, all subject to a 9.99% beneficial ownership blocker that holders may raise to 19.99% on 61 days' notice, with a 180-day lock-up barring sales after the merger closing. The stated purpose is investment, with no present plan or proposal to influence control, but Venrock partners Nimish Shah and Andrew Gottesdiener sit on Korsana's board and the group reserved the right to buy, sell, or participate in extraordinary corporate transactions.
CYCN: 8-K · acquisition merger
Cyclerion Therapeutics completed its previously announced merger with private biotech Korsana Biosciences on September 8, 2026, and the combined company now operates as Korsana Biosciences, Inc., trading on Nasdaq under the new ticker KRSA as of September 9, 2026 following a 1-for-7 reverse stock split. In connection with the closing, Korsana raised approximately $380.0 million in gross proceeds through a pre-closing PIPE of 140,516,748 shares and 20,171,986 pre-funded warrants, priced off a $268.4 million valuation for Korsana. Legacy Cyclerion securityholders retained only about 1.17% of the combined company on a fully diluted basis and received non-transferable contingent value rights tied to future sales of legacy assets, while Korsana investors hold approximately 98.83%; the post-merger fully diluted share count is roughly 55.1 million shares. Jonathan Violin, Ph.D. becomes CEO and President, Mark Vignola, Ph.D. CFO and Matthew Leoni, M.D. Chief Medical Officer, succeeding Cyclerion's departing leadership, and the company ceased to be a shell company as a result of the merger.
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
CYCN: 8-K · proxy statement
Cyclerion Therapeutics shareholders approved all merger-critical proposals at the August 26, 2026 annual meeting, including the issuance of more than 20% of shares outstanding to Korsana Biosciences stockholders and the resulting change of control, clearing a key hurdle for completion of the Korsana merger. The Cyclerion board finalized a 1-for-7 reverse stock split following the vote, expected to reduce shares outstanding from roughly 4.7 million to roughly 0.7 million. After the merger closes, the combined company is expected to begin trading on Nasdaq as Korsana Biosciences, Inc. under ticker KRSA at the open on September 9, 2026, with a new CUSIP of 23255M303. Shareholders rejected the proposal to redomesticate the company from Massachusetts to the Cayman Islands, so the combined company will remain a Massachusetts corporation, and approval was not a condition to closing the merger. Voters also approved an increase in authorized common shares from 400,000,000 to 700,000,000, elected six directors including CEO Regina Graul, and ratified Ernst & Young LLP as auditor for fiscal 2026.
Cyclerion Therapeutics' board fixed the close of business on September 4, 2026 as the record date for its previously announced distribution of contingent value rights (CVRs) to holders of record of the company's common stock and Series A Preferred Stock. The CVR Distribution is being made in connection with Cyclerion's planned merger with Korsana Biosciences, Inc., and the company has filed a Form S-4 containing a proxy statement/prospectus with the SEC for the transaction. The 8-K itself (Item 8.01) is procedural, and the filing reiterates that closing of the merger remains subject to conditions including shareholder approval, completion of a financing transaction, and Cyclerion's continued Nasdaq listing until closing.
CYCN: 425 · acquisition merger
Cyclerion Therapeutics filed a Form 425 on August 10, 2026 in connection with its proposed merger with Korsana Biosciences under the Agreement and Plan of Merger and Reorganization dated April 1, 2026. The two-step structure has Cyclerion's merger subsidiaries absorbing Korsana, which will continue as a wholly owned subsidiary of Cyclerion before merging into the second merger sub. On August 10, 2026, Cyclerion published communications about the transaction on its X and LinkedIn social media accounts, and this filing was made to publicize those posts under Rule 425. The filing contains no new deal terms, financial figures, or timeline updates beyond what was previously announced. The combined company is expected to advance KRSA-028, Korsana's product candidate for neurodegenerative diseases derived from the THETA platform, with a new name, Nasdaq listing and ticker symbol anticipated after closing. Closing remains conditioned on Cyclerion shareholder approval and completion of a financing transaction; the Form S-4 containing the proxy statement/prospectus (File No. 333-295175) has been filed with the SEC.
Cyclerion Therapeutics filed a Form 425 on August 6, 2026 disclosing that it published communications on its X and LinkedIn social media accounts regarding its proposed merger with Korsana Biosciences under the Agreement and Plan of Merger and Reorganization dated April 1, 2026. No new deal terms or financial figures were disclosed. Under the two-step structure, Cariboos Merger Sub Corp. will merge into Korsana, leaving Korsana a wholly owned subsidiary of Cyclerion, after which Korsana will merge into Cariboos Merger Sub II, LLC as part of the same overall transaction. The combined company is expected to advance Korsana's lead candidate KRSA-028 and its THETA platform targeting neurodegenerative diseases, with a new name, Nasdaq listing and ticker symbol anticipated following completion of the merger. Closing remains subject to Cyclerion shareholder approval and other conditions, and Cyclerion has filed a Form S-4 containing the proxy statement/prospectus.
CYCN: 10-Q · periodic report
Cyclerion Therapeutics disclosed substantial doubt about its ability to continue as a going concern in its Q2 2026 10-Q, reporting just $1.4 million of cash at June 30, 2026 against a $4.9 million net loss for the first half of the year and an accumulated deficit of $276.0 million. The filing warns that an investment in the stock is highly speculative and that holders could suffer a total loss of their investment. Survival hinges on the pending reverse merger with privately held Korsana Biosciences, which carries a concurrent $380.0 million pre-closing financing. Korsana holders are estimated to receive about 1.4735 Cyclerion shares per share, Cyclerion will be renamed Korsana Biosciences, Inc., the Form S-4 went effective on July 24, 2026, and closing is expected in Q3 2026 alongside a proposed reverse stock split. Operations are largely wound down: revenue was zero for the quarter, development of the CYC-126 treatment-resistant depression program is suspended due to cash limitations, and remaining value rests on Akebia praliciguat milestones of up to $557.5 million and a 10% stake in Tisento Therapeutics. If the merger fails, the company says it would need substantial new funding and may cease operations and dissolve, with pre-merger shareholders holding contingent value rights that may never pay out.
CYCN: 425 · leadership change
Cyclerion Therapeutics filed a Form 425 to disseminate a press release from its merger partner, Korsana Biosciences, announcing significant executive and board appointments. Korsana named Matthew Leoni, M.D. as Chief Medical Officer and Gan Wei, Ph.D. as Chief Technical Officer, while Heidi Henson was appointed to the Board of Directors as Chair of the Audit Committee to strengthen governance and technical capabilities. The press release reaffirmed that the previously announced reverse merger with Cyclerion is expected to close in the third quarter of 2026, with the combined company planning to trade on Nasdaq under the ticker symbol KRSA.
Cyclerion Therapeutics reported a net loss of $3.2 million for the quarter ended March 31, 2026, with zero revenue compared to $81,000 in the prior-year period. The company holds $2.8 million in cash and cash equivalents, which management estimates will fund operations only into the third quarter of 2026. The company entered into a definitive merger agreement with Korsana Biosciences, Inc. on April 1, 2026, which will result in Cyclerion changing its name to Korsana Biosciences, Inc. upon closing. Current Cyclerion shareholders are expected to own approximately 1.5% of the combined company, with Korsana securityholders owning the remaining 98.5% on a fully-diluted basis. Due to projected cash depletion and recurring operating losses, the company stated there is substantial doubt about its ability to continue as a going concern. The successful closing of the merger, anticipated in the third quarter of 2026, is critical to the company's future; if the merger is not consummated, the board may pursue dissolution and liquidation.
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is investigating Cyclerion Therapeutics regarding its proposed merger with Korsana Biosciences to determine if shareholders are receiving fair value. The law firm notes that upon closing, Cyclerion shareholders are expected to own approximately 1.5% of the combined company. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation on a contingency fee basis.
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
